Abstract:Systemic lupus erythematosus (SLE or lupus) is an immune-mediated disease associated with substantial medical burden. Notably, lupus exhibits a striking female bias, with women having significantly higher susceptibility compared to men, up to 14-fold higher in some ethnicities. Supernumerary X chromosome syndromes, like Klinefelter (XXY) and Triple X syndrome (XXX), also present higher SLE prevalence, whereas Turner syndrome (XO) displays lower prevalence. Taken together, SLE prevalence in different X chromosome dosage sceneries denotes a relationship between the number of X chromosomes and the risk of developing lupus. The dosage of X-linked genes, many of which play roles in the immune system, is compensated between males and females through the inactivation of one of the two X chromosomes in female cells. X-chromosome inactivation (XCI) initiates early in development with a random selection of which X chromosome to inactivate, a choice that is then epigenetically maintained in the daughter cells. This process is regulated by the X-Inactive-Specific Transcript ( XIST) , encoding for a long non-coding RNA, exclusively expressed from the inactive X chromosome (Xi). XIST interacts with various RNA binding proteins and chromatin modifiers to form a ribonucleoprotein (RNP) complex responsible for the transcriptional silencing and heterochromatinization of the Xi. This ensures stable silencing of most genes on the X chromosome, with only a few genes able to escape this process. Recent findings suggest that the molecular components involved in XCI, or their dysregulation, contribute to the pathogenesis of lupus. Indeed, nonrandom XCI, elevated gene escape from XCI, and the autoimmune potential of the XIST RNP complex have been suggested to contribute to auto-immune diseases, such as lupus. This review examines these current hypotheses concerning how this dosage compensation mechanism might impact the development of lupus, shedding light on potential mechanisms underlying the pathogenesis of the disease.

Is X chromosome inactivation a cause or effect of SLE?

Female-bias in systemic lupus erythematosus: How much is the X chromosome to blame?

Haematopoietic stem cell-derived immune cells have reduced X chromosome inactivation skewing in systemic lupus erythematosus

LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis

Skewed allelic expression on X chromosome associated with aberrant expression of XIST on systemic lupus erythematosus lymphocytes

lncRNA X-inactive-specific transcript is a potential biomarker related to changes in CD4 + T cell levels in systemic lupus erythematosus

Characterization of cxorf21 Provides Molecular Insight Into Female-Bias Immune Response in SLE Pathogenesis

Skewed escape from X-inactivation underlies female bias in Sjogren's syndrome

Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes

Altered X-chromosome inactivation predisposes to autoimmunity

Deconstructing the sex bias in allergy and autoimmunity: From sex hormones and beyond

Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants

Mechanisms underlying sex differences in autoimmunity

The aberrant expression of CD45 isoforms and levels of sex hormones in systemic lupus erythematosus

Human and Murine Toll-like Receptor-Driven Disease in Systemic Lupus Erythematosus

Mendelian Causes of Autoimmunity: the Lupus Phenotype

Implicating XIST in sex-biased autoimmunity

Systemic lupus erythematosus: a role for anti-receptor antibodies?

Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk

The Female-Biased Factor VGLL3 Drives Cutaneous and Systemic Autoimmunity.